A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT ID: NCT06602219
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
222 participants
INTERVENTIONAL
2024-10-25
2025-09-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
NCT06808815
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06176768
A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis
NCT03418493
A Study of LY3361237 in Participants With Psoriasis
NCT04975295
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
NCT01474512
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY4100511 Dose 1
Participants will receive LY4100511 orally.
LY4100511
Administered orally
LY4100511 Dose 2
Participants will receive LY4100511 orally.
LY4100511
Administered orally
LY4100511 Dose 3
Participants will receive LY4100511 orally.
LY4100511
Administered orally
Placebo
Placebo administered orally.
Placebo
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY4100511
Administered orally
Placebo
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).
* Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention.
* Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study
Exclusion Criteria
* Have a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis.
* Have any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus.
* Have a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment (including corticosteroids, immunosuppressants, and biologics).
* Have a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cahaba Dermatology Skin Health Center
Birmingham, Alabama, United States
Dermatology Trial Associates
Bryant, Arkansas, United States
Zenith Research, Inc.
Beverly Hills, California, United States
First OC Dermatology Research Inc
Fountain Valley, California, United States
Center for Dermatology Clinical Research
Fremont, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Clinical Science Institute
Santa Monica, California, United States
Driven Research
Coral Gables, Florida, United States
Direct Helpers Research Center
Hialeah, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
GCP Global Clinical Professionals, LLC
St. Petersburg, Florida, United States
ForCare Clinical Research
Tampa, Florida, United States
Endeavor Clinical Trials Center - Dermatology - Skokie
Skokie, Illinois, United States
Lawrence J Green, M.D, LLC
Rockville, Maryland, United States
Center for Clinical Studies, LTD.LLP
Webster, Texas, United States
Interior Dermatology Centre - Probity - PPDS
Kelowna, British Columbia, Canada
Skin Care West
Nanaimo, British Columbia, Canada
Simcoderm Medical & Surgical Dermatology Centre
Barrie, Ontario, Canada
Dermatrials Research Inc.
Hamilton, Ontario, Canada
Lovegrove Dermatology - Probity - PPDS
London, Ontario, Canada
DermEffects - Probity - PPDS
London, Ontario, Canada
Lynderm Research Inc.
Markham, Ontario, Canada
DermEdge Research
Mississauga, Ontario, Canada
Clintrial s.r.o.
Prague, Praha 10, Czechia
Pratia Pardubice a.s. - PRATIA - PPDS
Pardubice, , Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, , Czechia
Pratia Prague s.r.o. - PRATIA - PPDS
Prague, , Czechia
Kozni ambulance Fialova, s.r.o. - CRC - PPDS
Prague, , Czechia
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
Praxis Dr. med. Virgil-Oreste Mihaescu Facharzt fr Dermatologie und STD
Augsburg, Bavaria, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Hesse, Germany
Universitätsklinikum Münster
Münster, North Rhine-Westphalia, Germany
Universitätsklinikum Carl Gustav Carus an der TU
Dresden, , Germany
MensingDerma Research GmbH
Hamburg, , Germany
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hajdú-Bihar, Hungary
Allergo-Derm Bakos Kft
Szolnok, Jász-Nagykun-Szolnok, Hungary
Gyongyosi Bugat Pal Korhaz
Gyöngyös, , Hungary
MedMare Bt
Veszprém, , Hungary
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
Medical Corporation Kojinkai Sapporo Skin Clinic
Sapporo, Hakkaido, Japan
Katahira Dermatology Urology Clinic
Kagoshima, Kagoshima-ken, Japan
Ohyama Dermatology Clinic
Kumamoto, Kumamoto, Japan
Kume Clinic
Sakai-shi, Osaka, Japan
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan
Tachikawa Dermatology Clinic
Tachikawa, Tokyo, Japan
Shirasaki dermatology clinic
Takaoka, Toyama, Japan
Igarashi Dermatological Clinic
Tokyo, , Japan
AES - DRS - Synexus Polska Sp. z o.o. Oddzial we Wroclawiu
Wroclaw, Lower Silesian Voivodeship, Poland
Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska
Wroclaw, Lower Silesian Voivodeship, Poland
Clinical Best Solutions
Warsaw, Masovian Voivodeship, Poland
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
Rzeszów, Podkarpackie Voivodeship, Poland
AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdansku
Gdansk, Pomeranian Voivodeship, Poland
AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdyni
Gdynia, Pomeranian Voivodeship, Poland
Synexus Polska Sp. z o.o. Oddzial w Czestochowie
Częstochowa, Silesian Voivodeship, Poland
Laser Clinic Dermatologia Laserowa Medycyna Estetyczna
Szczecin, West Pomeranian Voivodeship, Poland
Centrum Medyczne Angelius Provita
Katowice, , Poland
Centrum Medyczne Reuma Park NZOZ
Warsaw, , Poland
Dermoklinika Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak
Lodz, Łódź Voivodeship, Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J5C-MC-FOAB
Identifier Type: OTHER
Identifier Source: secondary_id
18845
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.